These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4817854)

  • 1. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 3. Suppression of noradrenaline synthesis in sympathetic nerves by carbidopa, an inhibitor of peripheral dopa decarboxylase.
    Wurtman RJ; Watkins CJ
    Nature; 1977 Jan; 265(5589):79-80. PubMed ID: 834247
    [No Abstract]   [Full Text] [Related]  

  • 4. Carbidopa attenuation of L-DOPA emesis in dogs: evidence for a cerebral site of action outside the blood-brain barrier.
    Lotti VJ; Clark C
    Eur J Pharmacol; 1974 Mar; 25(3):322-5. PubMed ID: 4827858
    [No Abstract]   [Full Text] [Related]  

  • 5. Altered pattern of dopa metabolism.
    Fellman JH; Roth ES; Heriza EL; Fujita TS
    Biochem Pharmacol; 1976 Jan; 25(2):222-3. PubMed ID: 1259789
    [No Abstract]   [Full Text] [Related]  

  • 6. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 7. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
    Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 9. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 10. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
    Mrochek JE; Dinsmore SR; Ohrt DW
    Clin Chem; 1973 Aug; 19(8):927-36. PubMed ID: 4720815
    [No Abstract]   [Full Text] [Related]  

  • 12. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains.
    Horst WD; Bautz G; Renyi E; Spirt N
    Neuropharmacology; 1973 Dec; 12(12):1145-51. PubMed ID: 4782694
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain capillaries as a source of homovanillic acid in cerebrospinal fluid.
    Bartholini G; Tissot R; Pletscher A
    Brain Res; 1971 Mar; 27(1):163-8. PubMed ID: 5554221
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey.
    Bronaugh RL; Wenger GR; Garver DL; Rutledge CO
    Biochem Pharmacol; 1976 Jul; 25(14):1679-81. PubMed ID: 821489
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 17. Block of cerebral actions of L-dopa with methyl receptor substances.
    Cotzias GC; Tang L; Ginos JZ; Nicholson AR; Papavasiliou PS
    Nature; 1971 Jun; 231(5304):533-5. PubMed ID: 4934569
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 19. Decarboxylation of DL-2,4-dihydroxyphenylalanine (2,4-DOPA) to 2,4-dihydroxyphenylethylamine in mouse striatal slices.
    Orosz D; Cohen G
    Eur J Pharmacol; 1987 Apr; 136(3):441-4. PubMed ID: 3111867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
    Rivera-Calimlim L; Morgan JP; Dujovne CA; Bianchine JR; Lasagna L
    Biochem Pharmacol; 1971 Nov; 20(11):3051-7. PubMed ID: 5132112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.